Exozymes (EXOZ) Cash from Financing Activities (2023 - 2025)
Exozymes (EXOZ) posted quarterly Cash from Financing Activities of -$10554.0 for Q4 2025, down 100.07% year-over-year from $15.4 million in Q4 2024, and up 75.6% quarter-over-quarter from -$43254.0 in Q1 2025.
Exozymes (EXOZ) Cash from Financing Activities (2023 - 2025) Analysis & Trends
Exozymes (EXOZ) has reported Cash from Financing Activities for 3 consecutive years, with -$10554.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Financing Activities fell 100.07% year-over-year to -$10554.0; the TTM figure through Dec 2025 stood at $15.9 million (down 13.94% YoY), while the FY2025 annual figure was -$27709.0, down 100.15% from the prior year.
- Cash from Financing Activities grew to -$10554.0 in Q4 2025 per EXOZ's latest filing, from -$43254.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $15.4 million in Q4 2024 and bottomed at -$91507.0 in Q1 2024.
- Historically, Cash from Financing Activities has averaged $2.7 million across 3 years, with a median of $485000.0 in 2023.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities jumped 3075.94% — and 2025, when it plunged 100.07%.
- Exozymes' Cash from Financing Activities stood at $485000.0 in 2023, then surged by 3075.94% to $15.4 million in 2024, then slumped by 100.07% to -$10554.0 in 2025.
- Business Quant data shows EXOZ's Cash from Financing Activities at -$10554.0 in Q4 2025, -$43254.0 in Q1 2025, and $15.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Exozymes | 62.35 Mn | 62.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10,554.00 |
| Dec 31, 2025 | -10,554.00 |
| Mar 31, 2025 | -43,254.00 |
| Mar 31, 2025 | -43,254.00 |
| Dec 31, 2024 | 15.40 Mn |
| Dec 31, 2024 | 15.40 Mn |
| Sep 30, 2024 | 586,363.00 |
| Sep 30, 2024 | 586,363.00 |
| Jun 30, 2024 | 2.62 Mn |
| Jun 30, 2024 | 2.62 Mn |
| Mar 31, 2024 | -91,507.00 |
| Mar 31, 2024 | -91,507.00 |
| Dec 31, 2023 | 485,000.00 |
| Dec 31, 2023 | 485,000.00 |